Literature DB >> 22864766

Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus.

N Margreth van der Lugt1, Enrico Lopriore, Regina Bökenkamp, Vivianne E H J Smits-Wintjens, Sylke J Steggerda, Frans J Walther.   

Abstract

Patent ductus arteriosus (PDA) is a frequent complication in preterm infants. Ibuprofen and indomethacin (both COX inhibitors) are used for pharmacological closure of PDA. In most centers, a failed second course of COX inhibitors is followed by surgical closure. Our aim was to estimate the closure rate of clinically significant PDA after second and third courses of ibuprofen and record possible side effects. A study population, consisting of 164 preterm infants (<32 weeks' gestational age) with PDA admitted at our tertiary care center between November 2005 and September 2011, was retrospectively analyzed. Primary outcome was the closure rate after repeated courses of ibuprofen. The closure rate was similar after the first (109/164), second (24/43), and third (6/11) course of ibuprofen (X(2) = 2.1, p = 0.350). Late start of the first course of ibuprofen was a predictive factor for increased need of a second course (X(2) = 4.4, p = 0.036). No additional side effects of multiple courses of ibuprofen were detected. In conclusion, repeated courses of ibuprofen are an effective and safe alternative for surgical closure and should be considered after failure of the first course of ibuprofen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22864766     DOI: 10.1007/s00431-012-1805-6

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  28 in total

1.  Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity.

Authors:  Nancy Chorne; Carol Leonard; Robert Piecuch; Ronald I Clyman
Journal:  Pediatrics       Date:  2007-06       Impact factor: 7.124

2.  Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association.

Authors:  D D Marshall; M Kotelchuck; T E Young; C L Bose; L Kruyer; T M O'Shea
Journal:  Pediatrics       Date:  1999-12       Impact factor: 7.124

Review 3.  Patent ductus arteriosus of the preterm infant.

Authors:  Shannon E G Hamrick; Georg Hansmann
Journal:  Pediatrics       Date:  2010-04-26       Impact factor: 7.124

4.  A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.

Authors:  B Van Overmeire; K Smets; D Lecoutere; H Van de Broek; J Weyler; K Degroote; J P Langhendries
Journal:  N Engl J Med       Date:  2000-09-07       Impact factor: 91.245

5.  Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.

Authors:  Nandkishor S Kabra; Barbara Schmidt; Robin S Roberts; Lex W Doyle; Luann Papile; Avroy Fanaroff
Journal:  J Pediatr       Date:  2007-03       Impact factor: 4.406

6.  Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study.

Authors:  Shaul Dollberg; Ayala Lusky; Brian Reichman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-02       Impact factor: 2.839

Review 7.  The spectrum of leukomalacia using cranial ultrasound.

Authors:  L S de Vries; P Eken; L M Dubowitz
Journal:  Behav Brain Res       Date:  1992-07-31       Impact factor: 3.332

8.  Multiple courses of indomethacin and neonatal outcomes in premature infants.

Authors:  Madhavi Sangem; Sumita Asthana; Sanjiv Amin
Journal:  Pediatr Cardiol       Date:  2007-12-18       Impact factor: 1.655

Review 9.  Acute renal failure in neonates: incidence, etiology and outcome.

Authors:  F B Stapleton; D P Jones; R S Green
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

10.  An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study.

Authors:  Déborah Hirt; Bart Van Overmeire; Jean-Marc Treluyer; Jean-Paul Langhendries; Arnaud Marguglio; Mark J Eisinger; Paul Schepens; Saïk Urien
Journal:  Br J Clin Pharmacol       Date:  2008-02-27       Impact factor: 4.335

View more
  4 in total

1.  Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach.

Authors:  Andra Malikiwi; Charlene Roufaeil; Kenneth Tan; Arvind Sehgal
Journal:  Eur J Pediatr       Date:  2014-10-26       Impact factor: 3.183

2.  Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus.

Authors:  Brian C Gulack; Matthew M Laughon; Reese H Clark; Meera N Sankar; Christoph P Hornik; P Brian Smith
Journal:  Early Hum Dev       Date:  2015-09-19       Impact factor: 2.079

Review 3.  Patent ductus arteriosus in preterm infants: do we have the right answers?

Authors:  Hesham Abdel-Hady; Nehad Nasef; Abd Elazeez Shabaan; Islam Nour
Journal:  Biomed Res Int       Date:  2013-12-23       Impact factor: 3.411

4.  Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns.

Authors:  Robert B Flint; Rob Ter Heine; Edwin Spaans; David M Burger; Johan C A de Klerk; Karel Allegaert; Catherijne A J Knibbe; Sinno H P Simons
Journal:  Eur J Clin Pharmacol       Date:  2018-07-28       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.